Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023
- Consolidated revenues for fiscal 2023 were $31.3 million, a 3% increase from the previous year.
- Net loss for fiscal 2023 was $9.5 million, compared to a net income of $2.8 million in fiscal 2022.
- Costs of sales decreased by 4% while selling, general, and administrative expenses increased by 10%.
- The net loss was primarily due to a $13.1 million impairment related to the Duke License Agreement and a $3.7 million public bank inventory impairment charge.
- The company plans to transfer assets to a subsidiary for financial flexibility and potential spin-off to shareholders.
- Net loss of $9.5 million in fiscal 2023.
- Impairment charges of $13.1 million related to the Duke License Agreement.
- Public bank inventory impairment charge of $3.7 million.
- Increase in selling, general, and administrative expenses by 10%.
The reported net loss of $9.5 million by Cryo-Cell International for fiscal 2023 is a significant shift from the previous year's net income of $2.8 million. This change is primarily attributed to a non-cash impairment charge related to the Duke License Agreement and a public bank inventory impairment. While revenue showed a modest increase of 3%, the substantial impairment charges indicate a material event that investors should consider, particularly as it suggests a reassessment of the value of the company's assets.
The decision to transfer assets into a subsidiary and potentially spin it off could be viewed as a strategic move to unlock value and provide financial flexibility. However, investors should be aware that such corporate restructurings can also introduce new risks and uncertainties. The tax benefit recognized might offer some relief, but the core operational performance and future earnings potential remain key factors for valuation.
From a market perspective, the increase in processing and storage fee revenue suggests that Cryo-Cell's core services remain in demand, despite the overall net loss. The biobanking industry is known for high entry barriers and significant operational costs and Cryo-Cell's ability to increase revenue in this segment is positive. However, the decrease in product revenue and the impairment charges point towards potential challenges in product offerings and asset valuation that could impact market competitiveness.
Investors should monitor the company's subsequent actions regarding the proposed subsidiary and spin-off, as this could lead to a reevaluation of the company's market position and investor sentiment. The strategic focus on financial flexibility and future project funding could be indicative of a pivot or expansion in business strategy, which may alter the competitive landscape.
The mention of transferring assets related to the Duke University Patent and Technology License Agreement into a new subsidiary raises legal and regulatory considerations. Such a move will likely require careful legal structuring to ensure compliance with securities laws and protect shareholder interests. The potential spin-off will also entail a thorough examination of the regulatory implications, including the need for shareholder approvals and fair valuation practices.
Furthermore, the impairment charges that led to the net loss may attract regulatory scrutiny, as they require adherence to accounting standards for asset valuation and impairment testing. The company's disclosures and accounting practices in this regard will be critical in maintaining transparency and investor trust.
Financial Results
Revenue
Consolidated revenues for fiscal 2023 were
Net (Loss) Income
The Company reported a net loss of
Commentary
David Portnoy, Chairman of the Board and Co-CEO, commented, “In spite of the large non-cash charges, Cryo-Cell had another solid year in fiscal 2023. To provide more financial flexibility to fund future projects, we intend to transfer the assets related to the Duke University Patent and Technology License Agreement and certain other assets into a newly formed, wholly-owned subsidiary. Once such transfer is completed, we will explore spinning off this subsidiary to the Company’s shareholders.”
About Cryo-Cell International, Inc.
Founded in 1989, Cryo-Cell International, Inc. is the world’s first private cord blood bank. More than 500,000 parents from 87 countries have entrusted Cryo-Cell International with their baby’s cord blood and cord tissue stem cells. In addition to its private bank, Cryo-Cell International has a public banking program in partnership with Duke University. Cryo-Cell’s public bank has provided cord blood for more than 600 transplantations and operates cord blood donation sites across the
Cryo-Cell’s mission is to provide the premier cord blood and cord tissue cryopreservation services, to develop, manufacture and administer cellular therapies to significantly improve the lives of patients worldwide and to offer the highest quality and most cost effective biostorage solutions available. In February 2021, Cryo-Cell entered into a license agreement with Duke University that the Company believes has allowed Cryo-Cell to begin its transformation into an autonomous, vertically integrated cellular therapy company. In March 2022, Cryo-Cell launched ExtraVault to offer its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions. For more information, please visit (www.extravault.com).
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, you can identify forward-looking statements by terminology such as “will,” “may,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Generally, the words “anticipate,” “believe,” “continue,” “expect,” “intend,” “estimate,” “project,” “plan” and similar expressions identify forward-looking statements. In particular, statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance contain forward-looking statements.
We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. These forward-looking statements involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to differ from those expressed or implied by the forward-looking statements we make include, among others, risks related to: the impact of the COVID-19 pandemic on our sales, operations and supply chain, the success of the Company’s global expansion initiatives and product diversification, including its addition of the ExtraVault services, the Company’s actual future ownership stake in future therapies emerging from its collaborative research partnerships, the success related to its IP portfolio, the Company’s future competitive position in stem cell innovation, future success of its core business and the competitive impact of public cord blood banking on the Company’s business, the success of the Company’s initiative to expand its core business units to include biopharmaceutical manufacturing and operating clinics, the uncertainty of profitability from its biopharmaceutical manufacturing and operating clinics, the Company’s ability to minimize future costs to the Company related to R&D initiatives and collaborations and the success of such initiatives and collaborations and the success and enforceability of the Company’s umbilical cord blood and cord tissue license agreements, together with the associated intellectual property and their ability to provide the Company with royalty fees, along with the Risk Factors set forth in the Company’s Form 10-K filed on February 28, 2024.
This list of risks and uncertainties, however, is only a summary of some of the most important factors and is not intended to be exhaustive. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. These risks and uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. These forward-looking statements are made only as of the date hereof. Except as otherwise required by applicable law, we do not undertake and expressly disclaim any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. All subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by these cautionary statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228194119/en/
Irene Smith
813-749-2102
Ismith@cryo-cell.com
Source: Cryo-Cell International, Inc.
FAQ
What were Cryo-Cell International, Inc.'s (CCEL) revenues for fiscal 2023?
What was Cryo-Cell International, Inc.'s (CCEL) net loss for fiscal 2023?
What were the reasons for Cryo-Cell International, Inc.'s (CCEL) net loss in fiscal 2023?
What is Cryo-Cell International, Inc.'s (CCEL) plan to enhance financial flexibility?
What potential action does Cryo-Cell International, Inc. (CCEL) plan regarding its subsidiary?
